Christopher Tran
Primary Care · Moreno Valley, CANPI 1790382760
Payments from drug & device makers
Across 106 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$510
- AstraZeneca$341
- Bayer$269
- Lilly USA, LLC$208
- Nestle Healthcare Nutrition Inc.$176
- Pfizer$141
- plus $750 from 19 others
What the payments were for
- Food & beverage$2,396100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $510 |
| AstraZeneca | 17 | $341 |
| Bayer | 12 | $269 |
| Lilly USA, LLC | 5 | $208 |
| Nestle Healthcare Nutrition Inc. | 4 | $176 |
| Pfizer | 6 | $141 |
| AbbVie | 4 | $91 |
| GSK | 3 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Novartis | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Abbott | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Boehringer Ingelheim | 2 | $42 |
| Dynavax Technologies Corporation | 1 | $27 |
| Corcept Therapeutics | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $15 |
| Convatec Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,396 in reported general payments places this provider in the 85th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $34,906 |
| EliquisApixaban | 44 | $34,626 |
| RybelsusSemaglutide | 11 | $21,876 |
| OzempicSemaglutide | 22 | $20,255 |
| KerendiaFinerenone | 23 | $19,751 |
| TrulicityDulaglutide | 11 | $17,995 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,352 |
| FarxigaDapagliflozin Propanediol | 12 | $8,084 |
| AirsupraAlbuterol Sulfate/Budesonide | 13 | $5,916 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,256 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $2,958 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 157 | $2,942 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,809 |
| LantusInsulin Glargine,hum.Rec.Anlog | 15 | $2,654 |
| Atorvastatin Calcium | 174 | $1,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $510 | $42,13133 claims |
| Boehringer IngelheimJardiance | $42 | $34,90626 claims |
| PfizerEliquis | $141 | $34,62644 claims |
| BayerKerendia | $269 | $19,75123 claims |
| Lilly USA, LLCTrulicity | $208 | $17,99511 claims |
| AstraZenecaFarxiga, Airsupra | $341 | $14,00025 claims |
| GSKAnoro Ellipta | $74 | $10,35223 claims |
| Sanofi-aventis U.S. LLCLantus | $59 | $2,65415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 706 primary care providers in California.
Other primary care in Moreno Valley
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Joann BallPalm Desert$56K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.